Table 3.

Analysis of Anti-Interferon-γ Autoantibody Levels in the Thai and US Cohorts

A. Model Results for the Thai Cohort				B. Model Results for the US Cohort
Model 1	Value	SE	P Value	Model 1	Value	SE	P Value
Intercept	7.29	0.35	<.001	Intercept	7.26	0.29	<.001
Annual change	−0.07	0.02	<.001	Annual change	−0.04	0.02	.02
Infection	0.26	0.08	<.001	Infection	0.29	0.12	.02
Age at enrollment	−0.01	0.01	.19	Age at enrollment	0.01	0.01	.31
Male	0.21	0.14	.15	Male	−0.49	0.31	.13
Model 2	Value	SE	P Value	Model 2	Value	SE	P Value
Intercept	7.26	0.35	<.001	Intercept	7.31	0.32	<.001
Annual change	−0.06	0.02	<.001	Annual change	−0.04	0.02	.02
Infection	0.25	0.09	<.001	Infection	0.30	0.12	.02
Age at enrollment	−0.01	0.01	.19	Age at enrollment	0.01	0.01	.31
Male	0.21	0.14	.15	Male	−0.48	0.32	.15
Antibiotics	0.03	0.10	.79	Antibiotics	−0.06	0.15	.68
Model 3	Value	SE	P Value	Model 3	Value	SE	P Value
Intercept	7.45	0.36	<.001	Intercept	7.39	0.30	<.001
Annual change	−0.07	0.02	<.001	Annual change	−0.04	0.01	<.001
Infection	0.23	0.08	<.001	Infection	0.18	0.11	.10
Age at enrollment	−0.01	0.01	.10	Age at enrollment	0.01	0.01	.31
Male	0.23	0.15	.13	Male	−0.46	0.32	.17
Cyclophosphamide	−0.43	0.17	.01	Rituximab	−0.37	0.11	.001

Longitudinal trajectories of anti-interferon-γ autoantibody levels were assessed by fitting a linear mixed model adjusting for age, sex, and the presence of infection (model 1), antibiotic use alone (model 2), and cyclophosphamide or rituximab use (model 3).

Abbreviation: SE, standard error.